On March 12, 2026 Pamplona Therapeutics and Coherent Biopharma reported a strategic collaboration to combine Pamplona’s AI-driven targeted protein degradation (TPD) molecular design capabilities with Coherent’s dual-target conjugation technologies, Bi-XDC and C-PROTAC.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Through this partnership, the two companies will jointly explore a new class of degrader–conjugate therapeutics, integrating precision degrader design with advanced targeted delivery technologies. The collaboration aims to expand the therapeutic potential of targeted protein degradation, particularly in chronic diseases and other areas with significant unmet medical needs.
"We are excited to initiate this collaboration with Pamplona and Dr. Liu’s team. Our Bi-XDC technology platform is designed to address key limitations in drug delivery and conventional antibody-drug conjugates. By combining our delivery capabilities with Pamplona’s AI-driven degrader design, we believe this partnership can unlock new opportunities for innovative therapeutics."
Dr. Jinsong Liu, CEO of Pamplona Therapeutics, commented:
"Pamplona’s first First-in-Class molecule received FDA clearance for clinical investigation within three years, validating the engineering capability of our ASTRIDE platform in the TPD field. This collaboration brings together AI-enabled molecular design and next-generation delivery technologies, enabling us to accelerate the development of degrader–conjugate therapeutics and expand the boundaries of targeted protein degradation."
By integrating AI-powered degrader discovery with precision tissue/cell-targeting Bi-XDC delivery technologies, the collaboration seeks to enhance both the efficacy and targeting capabilities of protein degradation therapeutics. The combined approach aims to enable more effective elimination of disease-driving proteins while improving tissue targeting and pharmacological performance.
(Press release, Pamplona Therapeutics, MAR 12, 2026, View Source [SID1234663494])